Related Experiment Video
Updated: Jul 19, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Senescence program and its reprogramming in pancreatic premalignancy
Kailing Yang1, Xiaojia Li1, Keping Xie2,3,4
1Center for Pancreatic Cancer Research, The South China University of Technology School of Medicine, Guangzhou, China.
Abstract:
Tumor is a representative of cell immortalization, while senescence irreversibly arrests cell proliferation. Although tumorigenesis and senescence seem contrary to each other, they have similar mechanisms in many aspects. Pancreatic ductal adenocarcinoma (PDA) is highly lethal disease, which occurs and progresses through a multi-step process. Senescence is prevalent in pancreatic premalignancy, as manifested by decreased cell proliferation and increased clearance of pre-malignant cells by immune system. However, the senescent microenvironment cooperates with multiple factors and significantly contributes to tumorigenesis. Evidently, PDA progression requires to evade the effects of cellular senescence. This review will focus on dual roles that senescence plays in PDA development and progression, the signaling effectors that critically regulate senescence in PDA, the identification and reactivation of molecular targets that control senescence program for the treatment of PDA.
Related Concept Videos
Somatic to iPS Cell Reprogramming
Forced Transdifferentiation
Artificial...

